Toxoplasma vaccines: Appropriate end points and sample size in future human clinical trials

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 8, 2009, Pages 905-908

  Silveira, Claudio ^a   Gargano, Nicola ^b   Kijlstra, Aize ^c   Petersen, Eskild ^d  

^a Clinica Silveira   (Brazil)

^b Galileian Plus S Rl   (Italy)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TOXOPLASMA GONDII VACCINE;

CHILD HEALTH; CLINICAL RESEARCH; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFECTION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION CONTROL; NONHUMAN; PREVALENCE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADOLESCENT; ADULT; ANIMALS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; INFANT; PROTOZOAN VACCINES; SAMPLE SIZE; TOXOPLASMA; TOXOPLASMOSIS, OCULAR;

EID: 70350608214     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.81     Document Type: Editorial

References (30)

1. Jones JL, Muccioli C, Belfort R Jr et al. Recently acquired Toxoplasma gondii infection, Brazil. Emerg. Infect. Dis. 12, 582-587 (2006).
2. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int. J. Parasitol. 39(12), 1385-1394 (2009).
3. Bahia-Oliveira LM, Jones JL, Azevedo- Silva J et al. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg. Infect. Dis. 9, 55-62 (2003).
4. Ajzenberg D, Yera H, Marty P et al. Genotype of 88 Toxoplasma gondii isolates associated with toxoplasmosis in immunocompromised patients and correlation with clinical findings. J. Infect. Dis. 199, 1155-1167 (2009).
5. Khan A, Jordan C, Muccioli C et al. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg. Infect. Dis. 12, 942-949 (2006). (Pubitemid 43848416)
6. Belfort-Neto R, Nussenblatt V, Rizzo L et al. High prevalence of unusual genotypes of Toxoplasma gondii infection in pork meat samples from Erechim, southern Brazil. An. Acad. Bras. Cienc. 79, 111-114 (2007).
7. Khan A, Jordan C, Muccioli C et al. Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg. Infect. Dis. 12, 942-949 (2006). (Pubitemid 43848416)
8. Velmurugan GV, Dubey JP, Su C. Genotyping studies of Toxoplasma gondii isolates from Africa revealed that the archetypal clonal lineages predominate as in North America and Europe. Vet. Parasitol. 155, 314-318 (2008).
9. Sousa S, Ajzenberg D, Vilanova M et al. Use of GRA6-derived synthetic polymorphic peptides in an immunoenzymatic assay to serotype Toxoplasma gondii in human serum samples collected from three continents. Clin. Vac. Immunol. 15, 1380-1386 (2008).
10. Cook AJ, Gilbert RE, Buffolano W et al. Sources of Toxoplasma infection in pregnant women: European multicentre case-control study. Br. Med. J. 321, 142-147 (2000). (Pubitemid 30447005)
11. Bahia-Oliveira LM, Jones JL, Azevedo- Silva J et al. Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg. Infect. Dis. 9, 55-62 (2003).
12. Jongert E, Roberts CW, Gargano N, Förster-Wald E, Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem. Inst. Oswaldo Cruz. 104, 252-266 (2009).
13. SYROCOT Study Group. Individual patient data meta-ana lysis of prenatal treatment effect for congenital toxoplasmosis. Lancet 369, 115-121 (2007).
14. Glasner PD, Silveira C, Kruszon-Moran D et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am. J. Ophthalmol. 114, 136-144 (1992).
15. Silveira C, Belfort R Jr, Muccioli C et al. A follow-up study of Toxoplasma gondii infection in southern Brazil. Am. J. Ophthalmol. 131, 351-354 (2001).
16. Ronday MJ, Stilma JS, Barbe RF et al. Aetiology of uveitis in Sierra Leone, west Africa. Br. J. Ophthalmol. 80, 956-961 (1996).
17. Ayanru JO. The problem of uveitis in Bendel State of Nigeria: experience in Benin City. Br. J. Ophthalmol. 61, 655-959 (1977).
18. Gilbert RE, Stanford MR, Jackson H, Holliman RE, Sanders MD. Incidence of acute symptomatic toxoplasma retinochoroiditis in south London according to country of birth. Br. Med. J. 310, 1037-1040 (1995).
19. Ronday MJ, Stilma JS, Barbe RF, Kijlstra A, Rothova A. Blindness from uveitis in a hospital population in Sierra Leone. Br. J. Ophthalmol. 78, 690-693 (1994). (Pubitemid 24275553)
20. Gazzinelli RT, Brézin A, Li Q, Nussenblatt RB, Chan CC. Toxoplasma gondii: acquired ocular toxoplasmosis in the murine model, protective role of TNF-a and IFN-g. Exp. Parasitol. 78, 217-229 (1994). (Pubitemid 24176145)
21. Lu F, Huang S, Hu MS, Kasper LH. Experimental ocular toxoplasmosis in genetically susceptible and resistant mice. Infect. Immun. 73, 5160-5165 (2005). (Pubitemid 41105675)
22. Lu F, Huang S, Kasper LH. The temperature-sensitive mutants of Toxoplasma gondii and ocular toxoplasmosis. Vaccine 27, 573-580 (2009).
23. Buxton D, Thomson K, Maley S et al. Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet. Rec. 129, 89-93 (1991).
24. Kringel H, Dubey JP, Beshah E et al. CpG oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii. Vet. Parasitol. 123, 55-66 (2004).
25. Fox B, Bzik D. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature 415, 926-929 (2002). (Pubitemid 34174756)
26. Rosenberg C, De Craeye S, Jongert E et al. Induction of partial protection against infection with Toxoplasma gondii genotype II by DNA vaccination with recombinant chimeric tachyzoite antigens. Vaccine 27, 2489-2498 (2009).
27. Roestenberg M, McCall M, Hopman J et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009).
28. Bahia-Oliveira LM, da Silva JA, Peixoto-Rangel AL et al. Host immune response to Toxoplasma gondii and Ascaris lumbricoides in a highly endemic area: evidence of parasite co-immunomodulation properties influencing the outcome of both infections. Mem. Inst. Oswaldo Cruz 104, 273-280 (2009).
29. Lahmar I, Abou-Bacar A, Abdelrahman T et al. Cytokine profiles in toxoplasmic and viral uveitis. J. Infect. Dis. 199, 1239-1249 (2009).
30. Garweg JG, Candolfi E. Immunopathology in ocular toxoplasmosis: facts and clues. Mem. Inst. Oswaldo Cruz 104, 211-220 (2009).